Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.43 |
| ▸ | AKR1C4 | P17516 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.40 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14235748 | 0.83 | SMN1; SMN2 (0.41) | AKR1C3AKR1C2AKR1C1AKR1C4SMN1; SMN2 | |
| SCHEMBL23698351 | 0.82 | KDM4E (0.39) | SMN1; SMN2PTPN1XDHKDM4EMAPT | |
| SCHEMBL30678550 | 0.82 | KDM4E (0.39) | SMN1; SMN2PTPN1XDHKDM4EMAPT | |
| SCHEMBL20558544 | 0.79 | SMN1; SMN2 (0.41) | AKR1C3AKR1C2AKR1C1AKR1C4SMN1; SMN2 | |
| SCHEMBL20558627 | 0.79 | SMN1; SMN2 (0.41) | AKR1C3AKR1C2AKR1C1AKR1C4SMN1; SMN2 | |
| SCHEMBL1764708 | 0.79 | CA1 (0.37) | PARP1 | |
| SCHEMBL20558673 | 0.77 | SMN1; SMN2 (0.41) | AKR1C3AKR1C2AKR1C1AKR1C4SMN1; SMN2 | |
| SCHEMBL21729876 | 0.76 | SMN1; SMN2 (0.41) | AKR1C3AKR1C2AKR1C1AKR1C4SMN1; SMN2 | |
| SCHEMBL30863908 | 0.76 | SMN1; SMN2 (0.41) | AKR1C3AKR1C2AKR1C1AKR1C4SMN1; SMN2 | |
| SCHEMBL27942442 | 0.76 | SMN1; SMN2 (0.41) | SMN1; SMN2XDHSLC22A12KDM4EPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012419-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-18 | — | — | US | disclosed |
| CN-112752760-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-01-19 | — | — | CN | disclosed |
| US-20210347786-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-11 | — | — | US | disclosed |
| EP-3858838-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-08-04 | — | — | EP | disclosed |
| CN-112752760-A | Heterocyclic compounds | 武田药品工业株式会社 | 2021-05-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347786-A1 | HETEROCYCLIC COMPOUND | SLC10A2, ALPI, SLC10A1 | AKR1C3 549/4885AKR1C2 315/4885AKR1C1 307/4885 |
| US-12012419-B2 | Heterocyclic compound | SLC10A2, ALPI, SLC10A1 | AKR1C3 549/4885AKR1C2 315/4885AKR1C1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.